2021
DOI: 10.1016/j.rvsc.2021.01.012
|View full text |Cite
|
Sign up to set email alerts
|

A chimeric porcine reproductive and respiratory syndrome virus (PRRSV)-2 vaccine is safe under international guidelines and effective both in experimental and field conditions

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

1
5
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
5

Relationship

2
3

Authors

Journals

citations
Cited by 5 publications
(6 citation statements)
references
References 43 publications
1
5
0
Order By: Relevance
“…In this study, no viremia was observed in pigs inoculated with vCSL1-GP5-N44S. The chimeric GP5 mutants prepared in a similar way as in our study also showed low levels of viremia, and shedding and spreading were not observed [ 23 , 25 ]. We also expect that vCSL1-GP5-N44S is safe against shedding and circulation in field conditions, but further testing is required.…”
Section: Discussionsupporting
confidence: 56%
See 3 more Smart Citations
“…In this study, no viremia was observed in pigs inoculated with vCSL1-GP5-N44S. The chimeric GP5 mutants prepared in a similar way as in our study also showed low levels of viremia, and shedding and spreading were not observed [ 23 , 25 ]. We also expect that vCSL1-GP5-N44S is safe against shedding and circulation in field conditions, but further testing is required.…”
Section: Discussionsupporting
confidence: 56%
“…In a study in which neutralizing antibodies were transferred and then challenged using a young piglet model, it was suggested that neutralizing antibodies in blood at 3 (log 2 ) or higher could clear viremia [ 42 ]. Other studies found that high levels of neutralizing antibodies were associated with a low viral load in the blood post-challenge [ 25 , 43 ]. In this study, neutralizing antibodies to homologous strain in pigs inoculated with vCSL1-GP5-N44S reached a maximum of 4.50 ± 3.0 (log 2 ) at 42 dpi and reached 8.25 ± 0.96 (log 2 ) post-challenge.…”
Section: Discussionmentioning
confidence: 99%
See 2 more Smart Citations
“…In another previous study, it was observed that a chimeric PRRSV (K418) consisting of the structural gene of the LMY strain in the FL12 backbone produced cross-protection in vitro [32]. Subsequently, the same research team created deglycosylated K418 (K418DM), which was proven to be effective and safe under experimental and field conditions [33]. A recent study also reported that PRRSV chimeras that were modified using DNA shuffling methods with six heterologous PRRSV strains exhibited improved cross-protective efficacy against heterologous PRRSV strains [34].…”
Section: Introductionmentioning
confidence: 99%